RxDoctor Payments DataLook up a doctor →

Centrael Evans, MD

Ophthalmology · Athens, GANPI 1902249139

Payments from drug & device makers

$112,667in general payments, 2019–2025

Across 586 payments — averaging $192.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$57K
  • Rxsight Inc$42K
  • Alcon Research LLC$3K
  • Biotissue Holdings Inc.$2K
  • Sun Pharmaceutical Industries Inc.$1K
  • AbbVie$1K
  • plus $6K from 37 others

What the payments were for

  • Consulting fees$8,30011%
  • Speaking & faculty fees$38,48953%
  • Travel & lodging$11,32616%
  • Food & beverage$14,48820%
  • Gifts$640%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$112,667 in reported general payments places this provider in the 90th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$317,459
Medicare patients
914
Services billed
2,604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IlevroNepafenac95$36,023
RocklatanNetarsudil Mesylat/Latanoprost63$28,018
XiidraLifitegrast27$25,877
RestasisCyclosporine18$25,737
LumiganBimatoprost61$25,086
XdemvyLotilaner12$22,469
Cyclosporine13$17,390
VevyeCyclosporine11$16,878
CequaCyclosporine14$14,471
SimbrinzaBrinzolamide/Brimonidine Tart43$12,915
MieboPerfluorohexyloctane/Pf17$12,751
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol54$11,719
CombiganBrimonidine Tartrate/Timolol44$10,575
Travoprost61$9,380
Prednisolone Acetate180$6,173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$1,328$61,398123 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$404$38,62744 claims
NovartisIlevro$217$36,02395 claims
Aerie Pharmaceuticals, Inc.Rocklatan$343$28,01863 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$260$22,46912 claims
Harrow Eye, LLCVevye$311$16,87811 claims
Sun Pharmaceutical Industries Inc.Cequa$1,452$14,47114 claims
AlconSimbrinza$57,269$12,91543 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →